Subject to responses received through the expression of interest (EOI) process for Novavax COVID-19 vaccine that closed on Wednesday 26 January, sites approved for the administration of the vaccine are expected to be able to place orders for the new product in the Covid-19 Vaccine Administrative System (CVAS) starting early February.  

The Novavax COVID-19 vaccine will also be included in the standing EOI open for all general practices interested in expanding their participation in the Program. If general practices would like to take time to assess the need in their area, they can be onboarded at any time.  

The recommended schedule for administration is two doses, a minimum of three weeks apart.  

Novavax COVID-19 vaccine can be administered as part of a heterologous (mixed) primary schedule, if required, to people who have received one or more doses of another COVID-19 vaccine, including as a third dose for people who are severely immunocompromised. However, it is not currently recommended for use as a booster vaccine.  

The Novavax training module for health professionals administering vaccines is compulsory for all health professionals administering this vaccine. It is available here.